• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Thermo Fisher Scientific Inc

    11/24/25 4:51:27 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials
    Get the next $TMO alert in real time by email
    FWP 1 ny20059811x2-x3_fwp.htm FWP
    Issuer Free Writing Prospectus
    Filed Pursuant to Rule 433
    Registration Statement No. 333-285159
    333-285159-01
     
    Thermo Fisher Scientific (Finance I) B.V.

    €1,000,000,000 Floating Rate Senior Notes due 2027 (“Floating Rate Notes”)
    €1,100,000,000 3.628% Senior Notes due 2035 (“2035 Notes”)
     
    November 24, 2025
     
    Pricing Term Sheet

    Issuer:
    Thermo Fisher Scientific (Finance I) B.V.
       
    Guarantor:
    Thermo Fisher Scientific Inc.
       
    Legal Format:
    SEC Registered
       
    Securities:
    Floating Rate Senior Notes due 2027
    3.628% Senior Notes due 2035
       
    Expected Ratings (Moody’s / S&P / Fitch)*:
    A2 (Stable) / A- (Stable) / A- (Stable)
       
    Aggregate Principal Amount:
    Floating Rate Notes: €1,000,000,000
    2035 Notes: €1,100,000,000
       
    Stated Maturity Date:
    Floating Rate Notes: December 1, 2027
    2035 Notes: December 1, 2035
       
    Issue Price:
    Floating Rate Notes: 100.000% of the principal amount
    2035 Notes: 100.000% of the principal amount
       
    Coupon (Interest Rate):
    Floating Rate Notes: 3-month EURIBOR plus 0.280% per annum, paid quarterly in arrears; provided that the minimum interest rate will be zero.
    2035 Notes: 3.628% per annum, paid annually in arrears
       
    Mid-Swaps Yield:
    2035 Notes: 2.748%
       
    Spread to Mid-Swap:
    2035 Notes: +88 basis points
       
    Yield to Maturity:
    2035 Notes: 3.628%
       
    Benchmark Bund:
    2035 Notes: DBR 2.600% due August 2035
       
    Benchmark Bund Price / Yield:
    2035 Notes: €99.14 / 2.700%
       
    Spread to Benchmark Bund:
    2035 Notes: +92.8 basis points
       
    Interest Payment Dates:
    Floating Rate Notes: March 1, June 1, September 1 and December 1 of each year, beginning on March 1, 2026
    2035 Notes: December 1 of each year, commencing on December 1, 2026
       
    Day Count Convention:
    Floating Rate Notes: Actual/360
    2035 Notes: Actual/Actual (ICMA)
       
    Business Days:
    New York, London, T2
       
    Payment Business Day Convention:
    Floating Rate Notes: Modified following, unadjusted
    2035 Notes: Following, unadjusted

    Make-Whole Call:
    2035 Notes: +15 basis points (prior to September 1, 2035)
       
    Par Call:
    2035 Notes: On or after September 1, 2035
       
    Trade Date:
    November 24, 2025
       
    Settlement Date:
    December 1, 2025
       
    Currency of Payment:
    All payments of principal of, and premium, if any, and interest on, the notes, including any payments made upon any redemption of the notes, will be made in euro.  If the euro is unavailable to the issuer or, in the case of the guarantees, the guarantor, due to the imposition of exchange controls or other circumstances beyond the issuer’s or the guarantor’s control or if the euro is no longer being used by the then member states of the European Economic and Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions of or within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to the issuer, or, in the case of the guarantees, the guarantor or so used.
       
    Payment of Additional Amounts:
    Subject to certain exceptions and limitations, the issuer and the guarantor may be required to pay as additional interest to certain holders of notes such amounts as may be necessary so that every net payment on such holders’ notes after deduction or withholding for or on account of any present or future tax, assessment or other governmental charge of whatever nature imposed upon, or as a result of, such payment by the Netherlands or the United States (or any political subdivision or taxing authority thereof or therein), will not be less than the amount provided for in such holders’ notes to be then due and payable.
       
    Redemption for Tax Reasons:
    The issuer may redeem all, but not less than all, of a series of notes in the event of certain changes in the tax law of the Netherlands or the United States (or any political subdivision or taxing authority thereof or therein) if, in the written opinion of independent counsel chosen by the issuer or the guarantor, there is a material probability that the issuer or the guarantor will become obligated to pay additional interest on such series of notes as described above under “Payment of Additional Amounts.” The redemption would be at a redemption price equal to 100% of the principal amount of the notes to be redeemed, together with accrued and unpaid interest to, but not including, the date fixed for redemption.
       
    Purchase of Notes Upon a Change of Control Triggering Event:
    Upon the occurrence of a Change of Control Triggering Event (as defined in the prospectus supplement related to the notes), with respect to either series of notes, the issuer may, in certain circumstances, be required to make an offer to purchase such series of notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to, but excluding, the date of repurchase.
    2

    Denominations:
    €100,000 x €1,000
       
    ISIN / Common Code:
    Floating Rate Notes: XS3241801847 / 324180184
    2035 Notes: XS3241802811 / 324180281
       
    Expected Listing:
    The issuer intends to apply to list the notes on the New York Stock Exchange. The listing application will be subject to approval by the New York Stock Exchange. Upon such listing, the issuer will use commercially reasonable best efforts to maintain such listing and satisfy the requirements for such continued listing as long as the notes are outstanding.
       
    Trustee:
    The Bank of New York Mellon Trust Company, N.A.
       
    Paying Agent:
    The Bank of New York Mellon, London Branch
       
    Joint Book-Running Managers:
    Barclays Bank PLC
    BNP PARIBAS
    HSBC Continental Europe
    Morgan Stanley & Co. International plc
    Deutsche Bank Aktiengesellschaft
    Goldman Sachs & Co. LLC
    SMBC Bank EU AG
       
    Co-Managers:
    Academy Securities, Inc.
    AmeriVet Securities, Inc.
    Blaylock Van, LLC
    BNY Mellon Capital Markets, LLC
    BofA Securities Europe SA
    Citigroup Global Markets Europe AG
    ING Bank N.V. Belgian Branch
    J.P. Morgan SE
    KeyBanc Capital Markets Inc.
    Loop Capital Markets LLC
    Mizuho Bank Europe N.V.
    MUFG Securities (Europe) N.V.
    Nordea Bank Abp
    RBC Europe Limited
    Scotiabank (Ireland) Designated Activity Company
    U.S. Bancorp Investments, Inc.
    UBS AG London Branch
    Wells Fargo Securities Europe, S.A.

    * A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.  Credit ratings are subject to change depending on financial and other factors.
     
    We expect to deliver the notes against payment for the notes on or about December 1, 2025, which is the fifth London business day and fourth New York business day following the date of the pricing of the notes. Under Regulation (EU) No 909/2014, as amended, trades in the secondary market generally are required to settle in two business days in the place of settlement unless the parties to a trade expressly agree otherwise. Also, under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one New York business day, unless the parties to a trade expressly agree otherwise. Accordingly, purchasers who wish to trade notes before the first or second business day, as applicable, prior to December 1, 2025 will be required to specify alternative settlement arrangements to prevent a failed settlement.
    3

    The guarantor has filed a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) (including a prospectus), filed by the issuer and the guarantor, for the offering to which this communication relates.  Before you invest, you should read the prospectus in that registration statement, the prospectus supplement related to the offering and the other documents the guarantor has filed with the SEC for more complete information about the guarantor, the issuer and this offering.  You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.  Alternatively, the joint book-running managers can arrange to send you the prospectus and prospectus supplement related to the offering if you request it by calling Barclays Bank PLC at 1-888-603-5847, BNP PARIBAS at 1-800-854-5674, HSBC Continental Europe at 1-866-811-8049 or Morgan Stanley & Co. International plc at 1-866-718-1649.

    This pricing term sheet is not a prospectus for the purposes of (i) Regulation (EU) 2017/1129, as amended or (ii) Regulation (EU) 2017/1129 as it forms part of domestic law in the United Kingdom.
     
    MiFID II and UK MiFIR – professionals/ECPs-only / No PRIIPs KID or UK PRIIPs KID – Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as not available to retail investors in the EEA or the United Kingdom.
     
    The communication of this pricing term sheet, the prospectus supplement, the accompanying prospectus, any other related free writing prospectus and any other document or materials relating to the issue of each series of the notes described herein is not being made, and this pricing term sheet, the prospectus supplement, the accompanying prospectus, any other related free writing prospectus such other documents and/or materials have not been approved, by an authorized person for the purposes of section 21 of the United Kingdom’s Financial Services and Markets Act 2000, as amended. Accordingly, this pricing term sheet, the prospectus supplement, the accompanying prospectus, any other related free writing prospectus and such other documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. This pricing term sheet, the prospectus supplement, the accompanying prospectus, any other related free writing prospectus and such other documents and/or materials are for distribution only to persons who (i) have professional experience in matters relating to investments and who fall within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”)), (ii) fall within Article 49(2)(a) to (d) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are any other persons to whom it may otherwise lawfully be communicated or distributed under the Financial Promotion Order (all such persons together being referred to as “relevant persons”). This pricing term sheet, the prospectus supplement, the accompanying prospectus, any other related free writing prospectus and any such other document and/or materials are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this pricing term sheet, the prospectus supplement, the accompanying prospectus, any other related free writing prospectus and any such other document and/or materials relate will be engaged in only with relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this pricing term sheet, the prospectus supplement, the accompanying prospectus or any other related free writing prospectus relating to the issue of each series of the notes described herein or any of their contents.

    4
    Get the next $TMO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TMO

    DatePrice TargetRatingAnalyst
    9/11/2025$550.00Equal Weight → Overweight
    Barclays
    8/19/2025Outperform
    William Blair
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    7/11/2025$590.00Sector Perform → Sector Outperform
    Scotiabank
    7/9/2025$460.00Buy → Neutral
    UBS
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/14/2024Buy
    Redburn Atlantic
    More analyst ratings

    $TMO
    SEC Filings

    View All

    SEC Form FWP filed by Thermo Fisher Scientific Inc

    FWP - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    11/24/25 4:51:27 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form 10-Q filed by Thermo Fisher Scientific Inc

    10-Q - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    10/31/25 9:36:09 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

    10/29/25 6:05:40 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Thermo Fisher upgraded by Barclays with a new price target

    Barclays upgraded Thermo Fisher from Equal Weight to Overweight and set a new price target of $550.00

    9/11/25 8:36:39 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    William Blair initiated coverage on Thermo Fisher

    William Blair initiated coverage of Thermo Fisher with a rating of Outperform

    8/19/25 8:36:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Thermo Fisher from Buy to Hold and set a new price target of $510.00

    7/24/25 9:29:26 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

    Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") announced today that it has priced an offering of €2.1 billion aggregate principal amount (the "Offering") of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the "floating rate notes") at the issue price of 100.000% of their principal amount; and €1,100,000,000 aggregate principal amount of its 3.628% senior notes due 2035 (the "fixed rate notes," and together with the floating rate notes, the "notes") at the issue price of 100.000% of their

    11/24/25 9:10:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Thermo Fisher Scientific Receives 510(k) Clearance in the United States for EXENT System* to Aid in the Diagnosis of Multiple Myeloma

    First-of-its-kind, automated system delivers increased sensitivity, specific identification of disease markers and improved laboratory workflow to support fast, confident diagnoses Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced 510(k) clearance of the EXENT® Analyser and Immunoglobulin Isotypes (GAM) Assay**, a first-of-its-kind automated platform for clinical laboratories. The EXENT System combines enhanced sensitivity and automation to provide accurate results, helping clinicians make a fast diagnosis for patients with multiple myeloma and related disorders. According to the International Myeloma Foundation, more than 176,000 people are

    11/12/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Shafer Michael D exercised 10,725 shares at a strike of $262.39 and sold $6,435,000 worth of shares (10,725 units at $600.00) (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    11/26/25 5:24:37 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Sr. VP and CFO Williamson Stephen gifted 433 shares, decreasing direct ownership by 1% to 31,887 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    11/17/25 4:32:05 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Sr. VP and Chief HR Officer Britt Lisa P. sold $622,136 worth of shares (1,058 units at $588.26), decreasing direct ownership by 7% to 13,087 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    11/14/25 4:51:56 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/21/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    10/6/23 4:23:51 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

    Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

    7/23/25 9:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    908 Devices Appoints Christopher D. Brown to its Board of Directors

    908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

    6/16/25 8:00:00 AM ET
    $AAPL
    $MASS
    $RGEN
    Computer Manufacturing
    Technology
    Industrial Machinery/Components
    Industrials

    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/9/23 11:35:13 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/10/21 11:57:23 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $TMO
    Financials

    Live finance-specific insights

    View All

    Thermo Fisher Scientific Declares Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on January 15, 2026, to shareholders of record as of December 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the dev

    11/6/25 4:30:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific Reports Third Quarter 2025 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025. Third Quarter Highlights Third quarter revenue grew 5% to $11.12 billion. Third quarter GAAP diluted earnings per share (EPS) was $4.27, in-line with the prior-year quarter. Third quarter adjusted EPS grew 10% to $5.79. Delivered excellent operational performance in the quarter demonstrating the strength of our proven growth strategy, the power of our PPI Business System, and the continued active management of our company. Advanced our proven growth strategy, launching a range of high-impact, innovative new p

    10/22/25 6:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 22, 2025

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the third quarter 2025 before the market opens on Wednesday, October 22, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 761271. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under

    10/1/25 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials